Joint venture will create unrivalled biotechnology resource
International law firm, Bird & Bird, has recently advised Inpharmatica Ltd, a leading informatics-driven drug discovery company, on a joint venture with Celera Inc, a premier genomics company, which will lead to the development and commercialisation of the world's leading proprietary structural bioinformatics resource.
This new product, called Celera Edition BiopendiumTM, will apply Inpharmatica's proprietary protein structure prediction technology to Celera's proprietary mammalian protein sequences - and to all public domain protein sequences - to create a unique genome wide database. It will seamlessly link to the Celera Discovery System. Both companies believe this product will allow the most comprehensive precalculated analysis of sequence-structure relationships available. It will be jointly developed and co-marketed by both companies.
Commenting on the joint venture, lead partner, John Wilkinson, said:
"This will be a very important bioinformatics tool. The combination of technology and Celera's protein sequence data content will create a powerful resource for analysis of protein sequence, structure and functional annotation. I am very excited to be involved in this deal."
Celera Edition Biopendium will be jointly developed and co-marketed by both Celera and Inpharmatica. It will be launched in early 2002.
For any more information on this deal, please contact partner, John Wilkinson on +44 (0) 20 7415 6000.